This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode. In this NIS subject's data will be collected at one visit at the moment of discharge from the hospital. The results of the study would help to characterise the discrepancy between current clinical practice and treatment guidelines, indicating that atypical antipsychotics are preferable and should be used in monotherapy during acute psychotic episodes in subjects with schizophrenia. Available evidence have revealed a frequent use of first-generation antipsychotics, polypharmacy, intramuscular route of administration and use of atypical antipsychotics in doses lower than recommended in registered summary of product characteristics.
RECONNECT-S GAMMA : A non-interventional study to observe real-life usage of atypical antipsychotics in the acute inpatient management of schizophrenia.
Study Type
OBSERVATIONAL
Enrollment
503
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Győr, Hungary
Research Site
Kistarcsa, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Szekszárd, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Daugavpils, Latvia
Research Site
Jelgava, Latvia
Research Site
Liepāja, Latvia
...and 4 more locations
Description of used atypical antipsychotic(s) during hospitalisation
The data will be collected at one visit at the moment of discharge from the hospital.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of the daily dosage of atypical antipsychotic(s) during hospitalisation
The data will be collected at one visit at the moment of discharge from the hospital.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of mode of administration of atypical antipsychotic(s) during hospitalisation
The data will be collected at one visit at the moment of discharge from the hospital.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Percent of patients with atypical antipsychotic as monotherapy
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Percent of patients with combinations of antipsychotics.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of main criteria used for selection of an antipsychotic during hospitalisation.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of the usage of psychometric scales in day to day practice, to evaluate the disease symptoms and thus the efficacy of treatment.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of used concomitant psychiatric medication (other than atypical antipsychotic) during the hospitalization
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of the relationship between medication used during the hospitalization and maintenance therapy recommended upon discharge
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
Description of the study population by collecting the following exploratory variables: demographic, educational, economical, social data, psychiatric and somatic health.
Time frame: hospitalisation period, an expected average of 2 weeks (variable per patient)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.